Source: Zelira Therapeutics
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Zelira Therapeutics (ZLD) completes enrolment for its diabetic nerve pain drug trial
  • The trial will evaluate the efficacy and tolerability of Zelira’s proprietary medicinal cannabis product against an undisclosed multi-billion-dollar “big pharmaceutical” company drug
  • Zelira says this is a significant milestone for the study, which has been designed as a multi-arm head-to-head comparison of 60 subjects
  • Twenty patients in the trial’s investigative drug arm have been enrolled, with results expected by the end of the year
  • Zelira Therapeutics shares climb 7.44 per cent, trading at $1.30 at 1:15 pm AEST

Zelira Therapeutics (ZLD) has completed enrolment for its diabetic nerve pain drug trial.

The institutional review board-approved trial will evaluate the efficacy and tolerability of Zelira’s proprietary medicinal cannabis product against an undisclosed multi-billion-dollar “big pharmaceutical” company drug.

Zelira said this was a significant milestone for the trial, which had been designed as a multi-arm head-to-head comparison of 60 subjects, with 20 in each arm.

Zelira Therapeutics CEO and Managing Director Oludare Odumosu said this product trial exemplified Zelira’s strategy to continue generating clinical validation for cannabinoid-based medicines.

“We are very pleased with the rate of recruitment for this clinical trial and look forward to what we hope will be positive results,” Dr Odumosu said.

“The value proposition of Zelira has always been our ‘multiple shots on goal’ strategy that covers both our OTC products and our RX prescription products, that best positions our company for success, and that we continue to deliver on.”

Twenty patients in the trial’s investigative drug arm have already been completely enrolled, with results expected by the end of this year.

Zelira Therapeutics shares climbed 7.44 per cent, trading at $1.30 at 1:15 pm AEST.

ZLD by the numbers
More From The Market Online

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…